DAA use decreases risk for cardiovascular events in patients with advanced fibrosis, HCV

LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased risk for arrhythmias and conduction disorders.“Several studies have revealed that hepatitis C virus can induce chronic inflammation and immune dysregulation, and this immune dysregulation and chronic inflammation explained the development of extrahepatic manifestations in chronic hepatitis C patients, including cardiovascular disease,” Laurent Lam, MD, a physician and doctoral researcher at theRead More

Categories: News

Related Articles

HCV reinfection prevalence rises among MSM as acute cases decline

LONDON — Although the annual incidence of acute hepatitis C virus has decreased over the past 10 years in Frankfurt, Germany, the prevalence of HCV…

Combination glecaprevir, pibrentasvir with ezetimibe prevents HCV in transplantation

LONDON — Combined glecaprevir and pibrentasvir with ezetimibe prevented hepatitis C infection among patients who received non-liver solid organ transplants with HCV viremic grafts, according…

Post-treatment liver stiffness predicts complications, HCC in hepatitis C

SAN DIEGO — Liver stiffness assessment predicted liver-related complications and hepatocellular carcinoma development among patients with hepatitis C following direct-acting antiviral treatment, according to research.“HCV…

Liver fibrosis linked to CV events, survival in NAFLD, chronic kidney disease

LONDON — Elevated noninvasive markers of liver fibrosis correlated with an increased risk for cardiovascular events, end-stage renal disease and worse survival in patients with…

Antiviral combination plus standard therapy achieves ‘controlled biological state’ in HBV

LONDON — Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced HBsAg levels over 24 weeks compared with standard therapy, according to…